PROSPECTS FOR THE TREATMENT OF PROSTATITIS AND BENIGN ADENOMA WITH CIDIPOL, BASED ON NEW DATA ABOUT METABOLISM OF CIMINAL TO NITROGEN OXIDE (NO) AND NO-THERAPY ACHIEVEMENTS

Kravchenko V. G., Ivanov L. V., Shcherbak O. V.

DISCUSSIONS

Scentific article

Сurrently, in the treatment of chronic prostatitis and hyperplastic prostate processes, a large number of drugs, circuits and methods are used that do not always produce the desired results. In our previous study (18), the use of rectal administration of the preparation Cidipol for the treatment of prostatitis was suggested by careful extrapolation of the pharmacokinetics features of two low molecular weight, lipophilic, antimicrobial pharmaceutics – Ciminalum and Nitazole containing a nitroxyl group in its molecule. This made it possible to determine the main characteristics of the antimicrobial drug substance, the method of administration of drugs, the pharmacokinetic profile and parameters of pharmacokinetics, the composition of pharmaceutical adjuvants and the type of dosage form for the alleged successful treatment of prostatitis. In recent decades, the phenomenon of nitrogen oxide (NO) is actively considered as a powerful, although not fully elucidated medical-therapeutic reserve in the treatment of many diseases reserve in the treatment of many diseases. The purpose of this work is to analyse not only the possible positive effect of the NO – metabolite of Ciminalum on its pharmacokinetic profile, but also the effect of its NO – metabolite on various types of pharmacological activity when rectally administered for the treatment of prostatitis. This would have led to a significant increase in the evaluation of the efficacy of the drug Cidipol and to expand the spectrum of its pharmacological effects in combination with NO in the treatment of both prostatitis and other pathological processes in the rectum. Results and discussion. From the point of view of pharmacokinetics, Cidipol occurred to be a unique preparation, since when rectally used, in blood plasma, to our mind, both antimicrobial active pharmaceutical ingredient Ciminalum and its metabolic vasodilator NO present at the same time, which increases the bioavailability of Ciminalum in the systemic flow and adjacent tissue in the process of its metabolism. The presence in blood and pathologically altered adjacent tissues (urethra, prostate and rectum tissue) of the vasodilator and disaggregator of platelet NO allows the drug’s components (Ciminalum and its metabolite NO) to quickly and effectively penetrate into abovementioned substrates and to realize its pharmacological action. After rectal administration of cidipol, a fairly rapid appearance of the NO metabolite in the systemic circulation was detected, resulting in a vasodilator effect in the pelvic organs and a further noticeable increase in the concentration of Ciminalum in the systemic circulation (central chamber). It was also established to increase the level of the ascending branch and prolongation of the process of absorption of cinnamal, increase of the presence of the drug in pathologically altered tissues with manifestations of anti-inflammatory, reparative and antiandrogenic action. Conclusions. The preparation Cidipol is a pharmaceutical system, when being applied rectally, simultaneously presents in the blood plasma both as antimicrobial pharmaceutical Ciminalum and its metabolic vasodilator and platelets disaggregator NO, which increases the bioavailability of Ciminalum in the system flow and in adjacent tissues in the process of its metabolism. This makes it possible to quickly and efficiently penetration of the drug into pathological substrates and realize its pharmacological action.

Cidipol, API (Active pharmaceutical ingredient), Ciminalum, NO metabolite, prostatitis, BPH, pharmacokinetics

1. Kuznetsova VL, Solovyeva AG. Oksid azota: svoystva, biologicheskaya rol, mekhanizmy deystviya. Sovremennyye problemy nauki i obrazovaniya. 2015;4. Dostupno: htpp/www.science-education.ru/ [in Russian].
2. Furchgott R, Zawadzki J. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288:373-6.
3. Furchgott RF, Jothianandan D. Endothelium-dependent and independent vasodilation involving cyclic GMP: relaxation induced by nitric oxide, carbon monoxide and light. Blood Vessels. 1991;28:52-61.
4. Ignarro LG, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA. 1987 Dec;84(24):9265-9.
5. Boger RН, Bode-Boger SM, Thiele W, Junker W, Alexander K, Frölich JC. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arteriol occlusive olisease. Circulation. 1997 Apr 15;95(8):2068-74.
6. Bode-Bоger SM. Effect of L. arginine supplementation on NO production in man. European Journal of Clinical Pharmacology. 2006;62(13):91-9.
7. Drexler H, Zeiher AM, Meinzer K, Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L. Arginine. Lancet. 1991;338:1546-50.
8. Hon WM, Lee WH, Khoo HE. Nitric oxide in liver diseases. Annals of the New Jork Academy of sciences. 2002;962:278-95.
9. Kataoka H, Otsuka F, Ogura T, Yamauchi T, Kishida M, Takahashi M, et al. The role of nitric oxide and the rennin-angiotensin system in saltrestricted Dahl rats. H Am J Hypertens. 2001;14(3):276-85.
10. Kurioka S, Koshimura K, Sugitani M, Murakami Y, Nishiki M, Kato Y. Analysis of urinary nitric oxide metabolites in healthy subjects. Endocr. J. 1999;46(3):421-8.
11. Tomomi G, Masataka M. Nitric oxide and endoplasmic reticulum stress. Arteriosclerosis, thrombosis and vascular biology. 2006;26:1439-40.
12. Vinogradov NA. Antimikrobnyye svoystva okisi azota i regulyatsiya yeye biosinteza v makroorganizme. Dostupno: http://nature.web.ru/ [in Russian].
13. Vyrenkov YuYe, Yesipov AV, Musailov VA, Moskalenko VV, Shyshlo VK, Povalyayev AV. Primeneniye monooksida azota v khirurgicheskoy praktike. Fizioterapiya, balneologiya, reabilitatsiya. 2014;1:37-44. [in Russian].
14. Yefimenko NA. Rukovodstvo po primeneniyu apparata «Plazon» v khirurgicheskoy praktike. M.; 2003. 96 s. [in Russian].
15. Esipov AV, Lazarev AB. Primeneniye NO-terapii v lechenii bolnykh fibroplasticheskoy induratsiyey polovogo chlena (bolezn Peyroni). Sbornik tezisov XXXIX nauchno-prakticheskoy konferentsii vrachey 5 TSVKG VVS. 2008 May. s. 114-8. [in Russian].
16. Marakhonich LA, Pekshev AV, Yefimenko NA, Moskalenko VI. Perspektivy razvitiya plazmennoy khirurgii v voyennoy meditsine. Voyennomeditsinskiy zhurnal. 2008;4:32-5. [in Russian].
17. Moskalenko VI, Yesipov AV, Koridze AD, Neshchasnyy AG, Volkov AN, Moskalenko VV. Limfaticheskaya terapiya v voyennoy meditsine. Vestnik limfologii. 2008;1:11-7. [in Russian].
18. Hosseini A, Herulf M, Ehrén I. Measurement of nitric oxide may differentiate between inflammatory and non-inflammatory prostatitis. Scandinavian Journal of Urology and Nephrology. 2006;40(2):125-6.
19. Kravchenko VH, Kravchenko AV. Informatsiynyy lyst pro novovvedennya v systemi okhorony zdorovya: «Sposib likuvannya urohenitalnoho trykhomoniazu u zhinok». K.; MOZ U. Protokol № 3, 22.02.96. [in Ukrainian].
20. Kravchenko VG. Razrabotka sredstv i usovershenstvovaniye metodov individualnoy profilaktiki venericheskikh bolezney [dissertatsiya]. M.; 1985. 326 s. [in Russian].
21. Patent SSHA № 801, 444, Jan. 31, 1989. «Sredstvo dlya yndyvydualnoy profylaktyky venerycheskykh bolezney y lechenyya urohenytalnoho trykhomonyaza». Patent Ukrayiny № 104, 1992 r.; Patent Ros. Federatsyy № 1637807, 1993 h.; Patent Ukrayiny № 112956, 10.11.2016: «Antyseptychnyy likarskyy zasib z shyrokym spektrom farmakolohichnoyi diyi». [in Ukrainian].
22. Bezshapochnyy SB, Kravchenko VH, Hryshyna IS. Mikozy zovnishnoho vukha ta yikh ratsionalne likuvannya. Zhurnal vushnykh, nosovykh i horlovykh khvorob. 2017;2:22-8. [in Ukrainian].
23. Horbuntsov VV, Kravchenko VH. Lokalna terapiya kombinovanykh malaseziyno-piohennykh urazhen volosystoyi chastyny holovy. Materialy ХУ1 zyizdu Vseukrayinskoho likarskoho tovarystva. Kyyiv; 2017. s. 67. [in Ukrainian].
24. Kozak NV, Henyk BL, Torous IM, Prysyazhna SI. Tsydypol v kompleksniy terapiyi istynnoyi mikhurnytsi. Mater. Vseukrayinskoyi naukovopraktychnoyi konfer. molodykh uchenykh «Medychna nauka v praktyku okhorony zdorovya». Poltava; 2017. s. 27. [in Ukrainian].
25. Lebedyuk MM, Kravchenko VH, Zapolskyy EM, Lebedyuk KM. Eksperymentalne obgruntuvannya i klinichna otsinka protyvirusnykh vlastyvostey tsydypola-antyseptychnoho likarskoho zasobu z shyrokym spektrom farmakolohichnoyi diyi. Ukrayinskyy zhurnal dermat., venerol., kosmetol. 2017;1(63):99-105. [in Ukrainian].
26. Litvin OS, Dashchuk AM, vynakhidnyky. Sposib likuvannya vuhrovoyi khvoroby v stadiyi zahostrennya, poyednanoyi iz dysbiozom kyshechnyku. Patent Ukrayiny na vynakhid 27.11.2017. 5 s. [in Ukrainian].
27. Kravchenko VG, Khadzhay YaI, Lukashov SV, Levchenko VV. Eksperimentalnaya otsenka ostroy toksichnosti tsidipola – preparata dlya individualnoy profilaktiki venericheskikh bolezney. Dermatologiya i venerologiya. K.: «Zdorov’ya». 1988;23:94-7. [in Russian].
28. Kravchenko VH, Ivanov LV, Derymedved LV, Shcherbak OV. Farmakokinetychne obhruntuvannya terapevtychnoyi efektyvnosti antyseptychnoho preparata Tsydypol pry prostatytakh. Visnyk problem biolohiyi i medytsyny. 2018;4(2):143-8. [in Ukrainian].
29. Dorovskikh VA, Batalova TA, Sergiyevich AA, Urazova GE. Oksid azota v khimii, biologii i meditsine. GOU VPO «Amurskaya gosudarstvennaya meditsinskaya akademiya» Federal’nogo agentstva po zdravookhraneniyu i sotsial’nomu razvitiyu RF, Blagoveshchensk. 2007. 41 s. [in Russian].
30. Likhtenshteyn GI. Metod spinovykh metok v molekulyarnoy biologii. Moskva: Nauka; 1974. 256 s. [in Russian]. 31. Arnoldi EK. Khronicheskiy prostatit: problemy, opyt, perspektivy [monografiya]. Rostov na D.: «Feniks»; 1999. 320 s. [in Russian].
31. Shchetinin VV, Zotov YeA. Prostatit [nauchnaya monografiya]. M.: Meditsina; 2003. 488 s. [in Russian].
32. Yakovleva LV, Muzyka NYa. Dobroyakisna hiperplaziya peredmikhurovoyi zalozy, diahnostyka i likuvannya (ohlyad literatury). Klinichna farmatsiya. 2009;13(4):65-70. [in Ukrainian].
33. Ivanov LV. Izucheniye vzaimodeystviya nekotorykh gidrofilnykh nevodnykh rastvoriteley s biomembranami razlichnykh kletok metodami spinovykh i fluorestsentnykh zondov. Farmakom. 1999;2:45-7. [in Russian].

«Bulletin of problems biology and medicine» Issue 1 Part 1 (148), 2019 year, 15-19 pages, index UDK 615.28.015:616.65-002-085

10.29254/2077-4214-2019-1-1-148-15-19